Loading ......
Most antibody-drug conjugates carry cytotoxic payloads intended to kill a target cell. ABBV-3373 belongs to a different category, pairing a therapeutic antibody with a small-molecule immunomodulator so that the pharmacological effect is delivered to a restricted population of cells rather than distributed systemically. The concept addresses a familiar problem in immunology: small molecules that modulate immune signalling are effective but act everywhere, producing the systemic adverse effects that limit their use. Targeting them through an antibody narrows the distribution and changes the relationship between dose, exposure and effect. Quantifying such a molecule requires assays that distinguish the conjugate from its released payload, because the two have different pharmacokinetics and different biological consequences.
Figure 1. ABBV-3373 ADC ELISA for Immunomodulatory Payload Bioanalysis.
The bioanalytical strategy for an immunomodulatory conjugate begins with a question that cytotoxic conjugates rarely confront: what is the active species? For a cytotoxic payload the answer is usually the intracellular metabolite, and systemic exposure to that metabolite is an unwanted side effect to be measured for safety. For an immunomodulatory payload the released molecule may retain activity in circulation, so the distinction between targeted and systemic effects depends on how much payload escapes the conjugate and where it goes. Measuring intact conjugate describes targeted delivery, while measuring released payload describes the systemic exposure that the design was intended to minimise. Comparing the two over time reveals the stability of the linkage in circulation, and it allows a programme to demonstrate that the conjugate achieves its targeting objective rather than merely asserting it. Because the payload is not cytotoxic, conventional cytotoxicity-based potency assays are replaced by functional immunomodulatory readouts, which in turn require conjugate-specific quantitation to interpret.
| ABBV-3373 Species Tracked during Exposure Assessment | Details |
| Intact ABBV-3373 Conjugate | The intact molecule carries both targeting antibody and immunomodulatory payload, and it is the species responsible for cell-restricted delivery. Its measurement requires reagents that recognise the conjugated form without binding antibody that has already released its payload. |
| Released Immunomodulatory Payload | Payload that leaves the conjugate in circulation produces systemic exposure of the kind the design sought to avoid. Characterising it alongside intact conjugate quantifies the targeting efficiency achieved in vivo and informs the interpretation of systemic pharmacodynamic markers. |
| Antibody Backbone Exposure | Total antibody measurement describes the pharmacokinetics of the carrier and provides a stable comparator for conjugate results. Because the backbone persists after payload release, divergence between the two curves estimates deconjugation independently of clearance differences. |
| Immunogenicity Potential | Conjugation alters the antibody surface and can create neoepitopes that provoke anti-drug antibodies. Screening is particularly relevant for immunomodulatory conjugates, where an immune response could both accelerate clearance and confound the pharmacodynamic readouts used to assess activity. |
Dose selection for an immunomodulatory conjugate cannot rely on the maximum tolerated dose paradigm that governs cytotoxic agents, because the payload is not intended to kill cells and toxicity may arise from the immunomodulatory effect itself rather than from off-target cytotoxicity. Instead, selection depends on demonstrating that the conjugate achieves sufficient exposure at the target cell population while keeping systemic payload exposure within a range associated with acceptable immune modulation. That argument requires a coordinated measurement set: intact conjugate to establish targeted delivery, released payload to establish systemic escape, and pharmacodynamic markers to establish that the intended biology has been engaged. When these measurements are collected across a dose range, the resulting exposure–response relationship identifies a dose that saturates target delivery without proportionally increasing systemic exposure, which is precisely the profile a targeted immunomodulator should exhibit. Programmes that assemble this evidence early find that later decisions about dosing intervals, combination partners and patient selection rest on a coherent quantitative foundation rather than on empirical observation.
| Products | Core Advantages | Primary Applicable Scenarios |
| ABBV-3373 (ADC) ELISA Kit | A conjugate-specific immunoassay recognising the intact payload-bearing molecule in human and preclinical matrices, with reagents selected to avoid interference from released payload and unconjugated antibody. The format supports the dilution ranges used in clinical pharmacokinetic sampling and delivers reproducible quantitation across lots. | Conjugate exposure monitoring, targeting efficiency assessment, and comparability evaluation after process changes. |
| Intact MMAF ADC ELISA Kit | A platform method for intact conjugates carrying auristatin payload, providing an orthogonal readout that confirms whether a conjugate-specific assay is detecting the intended species. Its performance across multiple carriers makes it a useful benchmark for emerging programmes. | Orthogonal confirmation, payload-class benchmarking, and platform qualification. |
| MMAF ADC EIA Kit | Detects auristatin-bearing conjugate with a format suited to comparative work across payload chemistries. The assay provides a reference point for evaluating whether a novel conjugate behaves as expected for its payload class. | Payload comparison studies, method bridging, and confirmation of conjugate identity during development. |
| Human IgG subclass ELISA kit | Resolves human immunoglobulin subclasses to support characterisation of the antibody backbone used in conjugate construction. The assay performs consistently in serum and plasma and provides compositional information relevant to Fc-mediated clearance. | Backbone characterisation, reagent qualification, and investigation of subclass-related pharmacokinetic differences. |
Targeted immunomodulation requires evidence that the payload reaches the intended cells and largely stays there, and the assays below provide that evidence.
Targeted immunomodulation is an elegant idea that succeeds or fails on the quality of its exposure data. Demonstrating that a conjugate delivers its payload to the intended cells, and that it does not release that payload prematurely into circulation, requires assays capable of distinguishing the intact molecule from its components. The ABBV-3373 (ADC) ELISA Kit, supported by intact auristatin platform methods and human IgG subclass reagents, provides the measurement framework for that demonstration. For programmes exploring antibody-directed immune modulation, this combination delivers the reproducible quantitation and orthogonal context needed to translate a compelling mechanism into a defensible clinical strategy.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25409 | ABBV-3373 (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25411 | ABBV-221 (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......